Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

'A significant milestone in the field of chronic kidney disease' The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of

Related Keywords

,Daniel Gallego ,Eli Lilly ,Carinne Brouillon ,Boehringer Ingelheim ,Diabetes Obesity Global Medical Affairs ,European Kidney Patient Federation ,European Commission ,European Kidney Patient ,Human Pharma ,Leonard Glass ,Obesity Global Medical Affairs ,